Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a US-based clinical stage biotechnology company, announced on Wednesday that its clinical development partner, AgonOx, Inc, a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumour cells, has, in partnership with Providence Cancer Institute, completed the site initiation visit and can commence patient accrual for their collaborative clinical trial of PH-762.
The clinical trial is intended to evaluate the safety and the potential for improved therapeutic benefit from the administration of Phio's PH-762 treated 'double positive' (DP) CD8 tumour infiltrating lymphocytes (TILs) in subjects with melanoma and other advanced solid tumours. The trial will be carried out at Providence Cancer Institute in Portland, Oregon, by principal investigator Brendan Curti, MD, Medical Oncologist and Robert W Franz endowed chair for Clinical Research at the Earle A Chiles Research Institute, a division of Providence.
Phio Pharmaceuticals received FDA approval to start a clinical trial of intratumoral PH-762 in subjects with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The trial is likely to start in the second half of 2023.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration